Neumora Therapeutics
NMRA
98 hedge funds and large institutions have $41.1M invested in Neumora Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 40 closing their positions.
165% more call options, than puts
Call options by funds: $143K | Put options by funds: $54K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
5.63% less ownership
Funds ownership: 40.27% → 34.64% (-5.6%)
15% less funds holding
Funds holding: 115 → 98 (-17)
37% less capital invested
Capital invested by funds: $65.2M → $41.1M (-$24.1M)
40% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$798K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$543K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$491K |
| 4 |
Millennium Management
New York
|
+$389K |
| 5 |
AC
AlphaCore Capital
La Jolla,
California
|
+$256K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.63M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.86M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.04M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$803K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$604K |
NMRA Hedge Fund Activity: Q2 2025 in Review
98 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2025, worth a combined $41.1M — down 37% from $65.2M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of NMRA and 24 opened new positions — a net loss of 16 holders — while 28 trimmed existing stakes and 28 added.
The largest buyer was Two Sigma Advisers, adding an estimated $798K. The largest seller was BlackRock, cutting an estimated $2.63M.
- 98 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2025, down from 115 in Q1 2025.
- Funds reported $41.1M of Neumora Therapeutics stock for Q2 2025, down 37% quarter-over-quarter.
- 24 funds opened new Neumora Therapeutics positions in Q2 2025 and 40 closed out, a net change of -16 holders.
- The largest Neumora Therapeutics buyer in Q2 2025 was Two Sigma Advisers, an estimated $798K added.
- The largest Neumora Therapeutics seller in Q2 2025 was BlackRock, an estimated $2.63M sold.
Based on aggregated 13F filings for Q2 2025.